First line modified Folfirinox versus gemcitabine for advanced pancreatic cancer: A single institution retrospective experience
Background: Advanced pancreatic cancer (APC) is a highly lethal malignancy which has one of the worst treatment outcomes. Modified (m)FOLFIRINOX is an intense but a proven treatment approach with a survival benefit for APC. Although mFOLFIRINOX demonstrated survival benefit compared with gemcitabine...
Saved in:
Main Authors: | Emrah Eraslan, Fatih Yildiz, Gulnihal Tufan, Ferit Aslan, Umut Demirci, Omur Berna Oksuzoglu |
---|---|
Format: | Article |
Language: | English |
Published: |
Galenos Publishing House
2019-04-01
|
Series: | Journal of Oncological Sciences |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2452336418300761 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Complete response in borderline resectable pancreatic cancer after modified FOLFIRINOX chemotherapy followed by surgical resection: a case report
by: Seong Hyun Koh, et al.
Published: (2025-06-01) -
Well differentiated neuroendocrine tumors, a single center experience
by: Ece Esin, et al.
Published: (2018-12-01) -
Role of Oral Bacteria in Mediating Gemcitabine Resistance in Pancreatic Cancer
by: Geng Xu, et al.
Published: (2025-07-01) -
Factors Influencing Chemotherapy-Induced Taste Alterations in Cancer Patients Receiving Cisplatin Treatment: A Path Analysis
by: Berna Kurt PhD, et al.
Published: (2025-07-01) -
Short term real world safety data of pertuzumab use in HER2 targeted treatment of metastatic breast cancer
by: Ece Esin, et al.
Published: (2018-04-01)